Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (299)	10/10/2000 9:25:09 AM
From: nigel bates	Read Replies (1) \| Respond to of 438

Trickle - Oct. 10 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO - news) and Invitrogen Corporation (Nasdaq: IVGN - news) today announced that they have signed a licensing agreement granting Invitrogen exclusive worldwide rights to sell Genzyme Molecular Oncology's patented SAGE(TM) (Serial Analysis of Gene Expression) genomics technology in standardized reagent kits. The collaboration will substantially expand access to SAGE, enabling academic and commercial customers to increase their research productivity and more rapidly evaluate the role of genes in disease. Under the terms of the agreement, Genzyme Molecular Oncology will receive from Invitrogen an upfront payment and royalties on sales of each SAGE kit. The agreement will also enable Invitrogen to distribute Genzyme Molecular Oncology's proprietary bioinformatics software for analysis of SAGE results. ``Our SAGE technology is a powerful functional genomics and gene discovery tool that clarifies the role of genes in disease-the essential next step in transforming data from the Human Genome Project into valuable drug targets,'' said Gail Maderis, president, Genzyme Molecular Oncology. ``We are committed to making SAGE accessible to all genomics researchers who desire an open, highly quantitative system for the measurement of gene expression, and are excited to be working with Invitrogen to make this possible.'' Lyle Turner, chairman and chief executive officer, Invitrogen said, ``The SAGE technology licensed from Genzyme Molecular Oncology is a highly-sensitive tool for genome-wide expression profiling. By providing SAGE in a pre- optimized kit, Invitrogen will make this powerful and complex technology more accessible to academic and commercial researchers. We are extremely pleased to be working with Genzyme Molecular Oncology to provide customers with quality products for molecular biology, gene discovery and functional genomics research.'' The SAGE kit will enable new SAGE licensees an efficient means of incorporating the technology into their research efforts and will give existing SAGE licensees a convenient source of optimized and matched reagents. All SAGE users are able to access the growing public database of SAGE information as well as make comparisons with the proprietary SAGE data available on Compugen's LabOnWeb Internet site and from Celera Genomics, Inc.